Effects of magnesium supplementation on serum brain-derived neurotrophic factor levels and cognitive function in patients undergoing fluoxetine therapy for depression
Noor NJ, Syamsuddin S, Liaury K, Tawali S, Idris I, Azis I, Lisal ST
East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan · 0 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2026-06-30 · East Asian Arch Psychiatry · vol. 36 · número 2 · pág. 75
- Editorial
- Hong Kong Academy of Medicine
- Citado
- 0 citas · más que el 51% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- Acceso abierto (publicación gratuita) · CC-BY-NC-ND
- Áreas de investigación
- Treatment of Major Depression · Magnesium in Health and Disease · Schizophrenia research and treatment
- Palabras clave
- magnesium supplementation, brain-derived neurotrophic factor, fluoxetine, depression, cognitive function, attention, memory, adjunctive therapy, serum BDNF, Montreal Cognitive Assessment, young adults, mood stabilizers, valproic acid, lamotrigine, antiepileptic drugs, mood stabilizer side effects
- MeSH
- humans, magnesium, fluoxetine, brain-derived neurotrophic factor, antidepressive agents, second-generation, drug therapy, combination, depression, cognition, dietary supplements, adolescent, adult, middle aged, indonesia, female, male, young adult, cognitive enhancement
7 autores
- N J Noor🇮🇩Hasanuddin University
- Saidah Syamsuddin🇮🇩Hasanuddin University
- Kristian Liaury🇮🇩Hasanuddin University
- Suryani Tawali🇮🇩Hasanuddin University
- Irfan Idris🇮🇩Hasanuddin University
- I Azis🇮🇩Hasanuddin University
- Sonny Teddy Lisal🇮🇩Hasanuddin University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
To evaluate the effects of magnesium supplementation as an adjunct to fluoxetine on serum brain-derived neurotrophic factor (BDNF) levels and cognitive function in patients with depression.
Methods
Outpatients aged 18 to 50 years diagnosed with depression who were receiving fluoxetine treatment at various hospitals in Makassar, Indonesia, between July and August 2025 were invited to participate. Participants were randomly allocated to either the control group, which received fluoxetine therapy alone for 6 weeks, or the treatment group, which received fluoxetine therapy plus 350 mg of oral magnesium supplementation once daily for 6 weeks. Patients were assessed at baseline and 6 weeks. BDNF levels were measured using peripheral venous blood samples. Serum BDNF concentrations (in pg/mL) were quantified using an enzyme-linked immunosorbent assay kit. Cognitive function was assessed using the validated Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina).
Results
In total, 40 participants were randomly allocated to either the control group (n = 20) or the treatment group (n = 20). Both groups had significant improvements in MoCA-Ina scores from baseline to week 6 (both p < 0.001), but the improvement was greater in the treatment group (4.8 vs 1.35, p < 0.001), particularly in the domains of attention (from 2.90 to 4.05, p < 0.001) and memory (from 2.25 to 3.85, p < 0.001). At week 6, scores were significantly higher in the treatment group in the domains of attention (4.05 vs 3.10, p = 0.002), memory (3.85 vs 2.70, p < 0.001), and orientation (5.75 vs 5.05, p < 0.001). Although improvement in MoCA-Ina scores was greater in the treatment group, change in serum BDNF levels between groups was not significant (60.59 vs -29.01 pg/mL, p = 0.584). Changes in serum BDNF levels were more strongly correlated with changes in MoCA-Ina scores in the treatment group (ρ = 0.667, p = 0.001) than in the control group (ρ = 0.483, p = 0.031).
Conclusion
Magnesium supplementation as an adjunct to fluoxetine was associated with greater improvement in cognitive function than fluoxetine alone in patients with depression. Changes in serum BDNF levels were positively associated with cognitive improvement, particularly in the treatment group. These findings suggest a role for magnesium in enhancing cognitive recovery, possibly through modulation of neuroplasticity-related pathways.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.